Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients

NCT00055185 is registered in ClinicalTrials.gov with Progenics Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00055185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00055185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients
Lead sponsor
Progenics Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2003
Completion date
June 30, 2005
Enrollment
24
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acquired immune deficiency syndrome, hiv infections